SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001725160-23-000201
Filing Date
2023-11-13
Accepted
2023-11-13 17:24:19
Documents
1
Period of Report
2023-11-10

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1699914237.html 4  
1 FORM 4 wk-form4_1699914237.xml 4 3538
  Complete submission text file 0001725160-23-000201.txt   5094
Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Issuer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O ZENTALIS PHARMACEUTICALS, LLC 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address
Johnson David Michael (Reporting) CIK: 0001808098 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39263 | Film No.: 231400167